1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
Real-time Estimate Cboe Europe  -  03:42 2022-08-16 am EDT
318.28 CHF   +0.12%
01:21aSwiss Drugmaker Roche Gets US FDA Review for Lymphoma Treatment
MT
01:02aFDA Accepts Supplemental Biologics License Application for Genentech's Polivy Combination for People With Previously Untreated Diffuse Large B-Cell Lymphoma
BU
01:01aFDA accepts supplemental Biologics License Application for Roche's Polivy combination for people with previously untreated diffuse large B-cell lymphoma
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Roche's Chugai, Zenyaku Kogyo Win Japanese Nod For Rituxan Drug Against Neuromyelitis Optica

06/20/2022 | 05:39am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
CHUGAI PHARMACEUTICAL CO., LTD -0.08% 3865 Delayed Quote.3.56%
ROCHE HOLDING AG -0.08% 317.9 Delayed Quote.-16.14%
All news about ROCHE HOLDING AG
01:21aSwiss Drugmaker Roche Gets US FDA Review for Lymphoma Treatment
MT
01:02aFDA Accepts Supplemental Biologics License Application for Genentech's Polivy Combinati..
BU
01:01aFDA accepts supplemental Biologics License Application for Roche's Polivy combination f..
GL
08/15Novartis fails again to reuse anti-inflammatory drug to treat lung cancer
RE
08/15Roche Unveils New Diagnostic Test for COVID-19 Immune Response
MT
08/15Roche launches new diagnostic test for the better understanding of immune response to S..
GL
08/15Roche Launches New Diagnostic Test for the Better Understanding of Immune Response to S..
CI
08/14Switzerland Negotiating Pharmaceutical Trade Deal With US
MT
08/13U.S. and Switzerland working on facilitating pharma trade - U.S. ambassador
RE
08/12European shares rise as healthcare, leisure stocks gain
RE
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2022 64 249 M 67 994 M 67 994 M
Net income 2022 14 824 M 15 688 M 15 688 M
Net Debt 2022 10 272 M 10 870 M 10 870 M
P/E ratio 2022 17,1x
Yield 2022 3,04%
Capitalization 262 B 278 B 278 B
EV / Sales 2022 4,24x
EV / Sales 2023 4,12x
Nbr of Employees 100 920
Free-Float 82,4%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 317,90 CHF
Average target price 374,13 CHF
Spread / Average Target 17,7%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Officer
Christoph Franz Chairman
Levi A. Garraway Chief Medical Officer
Pascale Schmidt Chief Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG-16.14%277 502
JOHNSON & JOHNSON-2.91%436 680
ELI LILLY AND COMPANY13.66%298 298
PFIZER, INC.-15.75%279 215
ABBVIE INC.5.09%251 582
NOVO NORDISK A/S5.65%241 077